Atopic Dermatitis Clinical Trial
Official title:
Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin
Verified date | March 2018 |
Source | Derming SRL |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open clinical study to evaluate the soothing activity of a body cream to be applied once a day, mono-laterally at level of the antecubital fold and forearm, for an uninterrupted period of 1 month, by 22 adult volunteers, with positive anamnesis for atopy and habitual itching.
Status | Completed |
Enrollment | 22 |
Est. completion date | March 20, 2018 |
Est. primary completion date | March 20, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult volunteers of both sexes - volunteers with positive anamnesis for atopy and habitual itching - volunteers in a good general state of health in the Investigator opinion - negative pregnancy test (only for female subjects not in menopause) - accepting to follow the instructions received by the investigator - accepting to not change their habits regarding food, physical activity, body cleansing - agreeing not to apply or take any product/drug or use body massages able to change skin conditions during the entire duration of the study - accepting not to expose their face to strong UV irradiation (UV session, or sun bathes), during the entire duration of the study - no participation in a similar study currently or during the previous 3 months - volunteers who are giving a written informed consent. Exclusion Criteria: - Pregnancy (only for female subjects not in menopause) - lactation (only for female subjects not in menopause) - change in the normal habits in the last month - participation in a similar study during the previous 3 months - known allergy to one or several ingredients of the product on trial - insufficient adhesion to the study protocol - Dermatitis - presence of cutaneous disease on the tested area, as lesions, scars, malformations - clinical and significant skin condition on the test area. - Diabetes - endocrine disease - hepatic disorder - renal disorder - cardiac disorder - pulmonary disease - cancer - neurological or psychological disease - inflammatory/immunosuppressive disease - drug allergy. - Anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago) - using of drugs able to influence the test results in the investigator opinion. |
Country | Name | City | State |
---|---|---|---|
Italy | DERMING | Milano | MI |
Lead Sponsor | Collaborator |
---|---|
Derming SRL |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline of Transepidermal water loss (TEWL) | The measurement of TEWL, performed by the use of Tewameter® TM300, allows to objectively monitor skin responses to cosmetic treatments. A shift from low-normal rates of TEWL to high levels is due to barrier disruption. | Baseline (T0), 1 month (T1), 2 months (T2) | |
Primary | Change from baseline of Superficial skin hydration | Skin electrical capacitance value is measured with Corneometer CM825 | Baseline (T0), 1 month (T1), 2 months (T2) | |
Primary | Change from baseline of Deep skin hydration | Tissue dielectric constant of deep skin layers is measured with MoistureMeterD | Baseline (T0), 1 month (T1), 2 months (T2) | |
Primary | Change from baseline of Epicutaneous pH | Surface cutaneous pH is measured with pH meter HI5221 | Baseline (T0), 1 month (T1), 2 months (T2) | |
Primary | Change from baseline of Surface microrelief's regularity | Surface microrelief's regularity is performed on skin replicas images acquired by Primos | Baseline (T0), 1 month (T1), 2 months (T2) | |
Secondary | Change from baseline of itching sensation | Each volunteers scored its own itching sensation thanks to a visual analogic scale (VAS from 0 = no itching to 10= strong itching). | Baseline (T0), 1 month (T1), 2 months (T2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05018806 -
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04090229 -
A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis
|
Phase 1 | |
Terminated |
NCT03847389 -
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05388760 -
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
|
Phase 2 | |
Completed |
NCT05530707 -
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
|
N/A | |
Completed |
NCT02595073 -
Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis
|
Phase 3 | |
Recruiting |
NCT05509023 -
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
|
Phase 2 | |
Recruiting |
NCT05048056 -
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04598269 -
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
|
Phase 2 | |
Recruiting |
NCT03936335 -
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
|
||
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT05029895 -
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
|
||
Terminated |
NCT03654755 -
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04556461 -
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function
|
Phase 2 | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Completed |
NCT03719742 -
A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer
|
N/A | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03441568 -
In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control
|
N/A | |
Recruiting |
NCT06366932 -
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
|
Phase 4 | |
Completed |
NCT03304470 -
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
|
Phase 2 |